Compliance

Rule 701 and the $10 Million Line: The Securities Rule Behind Every Startup Option Grant

Rule 701 lets private startups grant stock options without SEC registration, until you cross $10M in a year. How the exemption works and what changed in 2026.

By 409.AI Team - 2026-07-31

# Rule 701 and the $10 Million Line: The Securities Rule Behind Every Startup Option Grant

Every time your startup grants a stock option, it's selling a security. That sounds dramatic, but it's the plain reading of the Securities Act of 1933. A stock option is a security, and offering one to an employee is an offer to sell one. In public markets that triggers a registration statement and a mountain of paperwork. Private startups skip all of it because of a single narrow exemption, and most founders have never actually read it.

That exemption is Rule 701. It's the reason your cap table full of ISOs and RSUs isn't sitting in an SEC filing. In March 2026 the SEC's Division of Corporation Finance refreshed its guidance on how the rule works, which is a good excuse to understand what you've been relying on all along.

What Rule 701 actually exempts

Rule 701 (17 CFR 230.701) exempts compensatory equity issued by private companies from Securities Act registration. If you're not an Exchange Act reporting company, meaning you're private, and you grant options, restricted stock, RSUs, or sell shares to employees, officers, directors, and certain consultants under a written compensatory benefit plan, Rule 701 covers the offer and sale.

The operative word is compensatory. Rule 701 is for equity you hand out as pay, not equity you sell to raise money. A SAFE sold to an angel rides a different exemption, usually Regulation D. The option you grant a new engineer rides Rule 701. If you want the fuller picture of how those financing instruments interact with your equity, we walk through it in [how SAFEs affect your 409A valuation](https://409.ai/articles/how-safes-affect-your-409a-valuation).

One thing to keep straight: Rule 701 only handles federal registration. State blue-sky laws and the antifraud provisions still apply, and the exemption doesn't turn your grant into a registered, freely tradable security. It keeps you out of the registration regime, nothing more.

The ceiling most startups never hit

Rule 701 isn't unlimited. Under 701(d), the total you can issue in any consecutive 12-month period is capped at the greatest of three numbers:

$1,000,000
15% of the company's total assets
15% of the outstanding amount of the class of securities being offered, usually common stock

For a company with real assets or a sizable common pool, the two 15% tests almost always beat the $1M floor, so this ceiling rarely bites a growing startup. The number that trips people up isn't the 701(d) cap. It's the disclosure threshold that sits right next to it in 701(e).

The $10 million disclosure trigger

Here's the part that catches finance teams off guard. If the aggregate sales price or amount of securities you issue under Rule 701 in any consecutive 12-month period tops $10 million, you have to hand every recipient a real disclosure package before the sale.

That line used to be $5 million. The SEC doubled it to $10 million in final rules adopted in July 2018, following a mandate in the Economic Growth, Regulatory Relief, and Consumer Protection Act. Ten million has been the trigger ever since.

How do you count toward it? Options count at their exercise price, and RSUs and restricted stock count at their value, measured on the grant date rather than when an option vests or gets exercised. Say you grant 2,000,000 options with a $4.00 strike. That's $8 million against the threshold the day you grant them, whether or not a single option is ever exercised. Layer in a few RSU grants and a small secondary sale, and a well-funded Series B can cross $10 million in one year without anyone circling the date.

What you actually have to disclose

Once you're over the line, 701(e) requires you to deliver to every award recipient, a reasonable time before the grant, exercise, or sale:

A copy of the compensatory plan or the underlying contract.
Risk factors describing what's risky about holding the stock.
Financial statements, including a balance sheet plus income, cash flow, and stockholders' equity statements, prepared to the standard of Form 1-A Part F/S and no more than 180 days old as of the sale date.

That 180-day rule is the real operational headache. Financials go stale. If you cross the threshold and keep granting quarterly, you need reasonably current statements on hand every time, which usually means keeping your books close to audit-ready year round. This is the point where a company's securities counsel and its finance team have to actually talk to each other.

What the SEC clarified in March 2026

On March 6, 2026, the SEC's Division of Corporation Finance issued new and revised Compliance and Disclosure Interpretations (CDIs) for Rule 701. None of them rewrote the rule, but they settled several questions that startups and their lawyers had been guessing at:

**Electronic delivery counts.** The disclosures can go out as an email with attachments. Rule 701(e) only requires that the information be provided and delivered, with no particular medium mandated.
**Foreign private issuers are covered.** A non-US private company granting equity to its people can lean on Rule 701 the same way a Delaware startup does.
**Timing follows the instrument.** Disclosure has to reach the recipient a reasonable time before the operative date, and that date is the grant date for RSUs, the exercise date for options, and the sale date for stock.

If you're a global company weighing IFRS 2 against ASC 718 for your equity accounting, the same grants that raise those questions are the ones Rule 701 governs on the securities side. We compare the two frameworks in [IFRS 2 vs. ASC 718](https://409.ai/articles/ifrs-2-vs-asc-718-share-based-payment).

Where your 409A comes in

Rule 701 and your 409A valuation are quietly wired together. Your 409A sets the fair market value of your common stock, which sets the exercise price on your ISOs and NSOs. That exercise price is exactly the number that counts toward the $10 million threshold. If the 409A basics are hazy, start with [what a 409A valuation is](https://409.ai/articles/what-is-a-409a-valuation-a-comprehensive-guide) and how [ISOs and NSOs are taxed](https://409.ai/articles/iso-vs-nso-how-stock-options-are-taxed).

So a higher 409A pulls in two directions at once. It raises strike prices, which is good for your 409A safe harbor and for employee tax treatment, and it pushes each grant's dollar value up against the Rule 701 ceiling faster. A company doing large annual refresh grants right after a big markup can land over $10 million sooner than last year's math implied. It's worth modeling the 409A and the 701 numbers together, especially in the 12 to 18 months before an IPO, when both grant volume and valuations climb. We get into that window in [409A valuations for pre-IPO stock options](https://409.ai/articles/409a-valuations-for-pre-ipo-stock-options).

What happens if you get it wrong

Missing Rule 701 isn't a footnote. Exceed the 701(d) cap, or fail to deliver the required 701(e) disclosures once you're over $10 million, and you can lose the exemption for the affected sales. That can hand employees rescission rights, the ability to unwind the purchase and get their money back, and it exposes the company to securities-law liability. Those are precisely the issues acquirers and IPO underwriters dig up in diligence. This is a call-your-securities-counsel situation, not a spreadsheet fix.

It also compounds with your equity accounting. The same grants live in your [ASC 718 stock-based compensation expense](https://409.ai/articles/asc-718-stock-based-compensation-startup-guide), and a Rule 701 problem surfaced during a financing or acquisition can force uncomfortable talk of restatements and indemnities. If you're running a liquidity event for employees, the securities analysis gets more involved still, which is why we treat it separately in [tender offers and secondary sales](https://409.ai/articles/tender-offers-secondary-sales-409a-valuation).

The practical takeaway

Rule 701 is the kind of rule that stays invisible right up until it isn't. For an early-stage company granting a handful of options a quarter, it hums along in the background. For a Series B or later company doing large refresh grants on a freshly marked-up 409A, the $10 million disclosure line is a live operational trigger that turns your option program into a securities-disclosure obligation the moment you cross it.

The fix isn't complicated. Track your trailing 12-month Rule 701 total the same way you track your option pool, know roughly how close you are to $10 million, and keep financials current enough to satisfy the 180-day rule before you get there. Do that, and the March 2026 CDIs are just confirmation you're already handling it. Skip it, and you learn about the gap during diligence, which is the worst possible moment to find out.